What Is MoonLake Immunotherapeutics Afraid Of?

STAT framed this not as a one-time slip but as a pattern of data obtuseness at MoonLake. That distinction matters. A single vague press release is annoying. A pattern suggests a strategy.

The Bigger Picture: Biotech's Transparency Problem

MoonLake isn't operating in a vacuum here. Clinical-stage biotechs have a long, messy history with data disclosure. A Yale/Bioethics International study found that only 26% of FDA-approved products had publicly available results for all the trials that supported their approval. Even more striking: 42% of FDA-approved drugs failed the agency's own transparency requirements.

The study also found that larger companies tend to be significantly more transparent than smaller ones.

During COVID, biotech leaders publicly argued that trial data should never be released by press release alone, because incomplete announcements distort both scientific and market interpretation. One researcher quoted by STAT made a sharp comparison: announcing favorable clinical data without supporting evidence is like a CEO announcing earnings without providing the financial statements. The SEC wouldn't tolerate that from a bank. Why should investors tolerate it from a biotech?

Why This Stings More for MoonLake

The timing couldn't be worse. MoonLake's stock (MLTX) has been in rough shape, falling roughly 65% over the past twelve months. Analysts remain split on whether the company is a bargain or a trap. But Guggenheim simply reaffirmed its existing Buy without raising its price, which reads more like polite encouragement than conviction.

For a stock that's lost two-thirds of its value in a year, trust is the scarcest currency. An investigation questioning your willingness to share data is the last thing you need when you're already asking investors to take a leap of faith.

The Drug Itself Is Actually Interesting

Which makes the opacity all the more frustrating, because sonelokimab has a genuinely novel design. It's a nanobody, a smaller, more nimble cousin of traditional antibodies. Think of regular antibodies as SUVs and nanobodies as motorcycles: they can squeeze into tighter spaces, potentially reaching inflamed tissue that bulkier drugs can't access easily.

Sonelokimab has three binding domains. Two of them block IL-17A and IL-17F, inflammatory signals that drive diseases like psoriatic arthritis and hidradenitis suppurativa (a brutal skin condition involving painful, recurring abscesses). The third domain latches onto albumin, a blood protein, which extends the drug's life in the body and may help concentrate it where inflammation is worst.

The pipeline beyond psoriatic arthritis is substantial. MoonLake's Phase 3 HS program (the VELA-1 and VELA-2 trials) has already reported Week 52 results with no new safety concerns, and the company says its pre-BLA process for HS is complete, with a regulatory submission planned by the end of September 2026. That filing, if it happens on schedule, would be MoonLake's first real shot at becoming a commercial-stage company.

So What Happens Next?

The IZAR-1 trial remains blinded and will continue to Week 52, with a full readout expected in the first half of 2027. A second psoriatic arthritis trial (IZAR-2) is still enrolling patients, with completion expected in Q3 2026. Both readouts will eventually force MoonLake's hand: you can't file for FDA approval without showing your full dataset.

The question isn't whether the data will eventually come out. It will. The question is why MoonLake seems so reluctant to show its cards now, when transparency could rebuild investor confidence at a moment the company desperately needs it.

In biotech, silence rarely inspires confidence. If the data is as positive as MoonLake says, the smartest move would be to prove it. Because right now, the loudest signal investors are hearing isn't the trial results. It's the quiet.